ARS Pharmaceuticals, Inc Cash Flow Conversion Efficiency
ARS Pharmaceuticals, Inc cash flow conversion efficiency. Based on the latest financial reports, ARS Pharmaceuticals, Inc (SPRY) has a cash flow conversion efficiency ratio of -0.381x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.48 Million) by net assets ($114.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ARS Pharmaceuticals, Inc (2018–2025)
Cash flow conversion efficiency of ARS Pharmaceuticals, Inc from 2018 to 2025. This chart illustrates how ARS Pharmaceuticals, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ARS Pharmaceuticals, Inc share price for real-time trading data and today's change.
ARS Pharmaceuticals, Inc Cash Flow Conversion Ratio Explained
ARS Pharmaceuticals, Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ARS Pharmaceuticals, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ARS Pharmaceuticals, Inc ranked by their cash flow conversion efficiency. Also see market cap of ARS Pharmaceuticals, Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FVCBankcorp Inc
NASDAQ:FVCB
|
0.062x |
|
Schweizerische Nationalbank
SW:SNBN
|
0.000x |
|
Qingdao Richmat Intelligence Technology Co. Ltd. A
SHE:301320
|
N/A |
|
KNEAT.COM INC.
F:FOBK
|
-0.047x |
|
NN Inc
NASDAQ:NNBR
|
0.142x |
|
Insyde Software
TWO:6231
|
0.104x |
|
Chin Hin Group Property Bhd
KLSE:7187
|
-0.065x |
|
Guolin Environmental Tech Co Ltd
SHE:300786
|
0.001x |
Annual Cash Flow Conversion Efficiency for ARS Pharmaceuticals, Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of ARS Pharmaceuticals, Inc from 2018 to 2025. Review ARS Pharmaceuticals, Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $114.26 Million | $-170.87 Million | -1.495x | -2934.56% |
| 2024-12-31 | $256.80 Million | $13.55 Million | 0.053x | +120.54% |
| 2023-12-31 | $230.76 Million | $-59.27 Million | -0.257x | -74.87% |
| 2022-12-31 | $272.89 Million | $-40.08 Million | -0.147x | -126.15% |
| 2021-12-31 | $-31.27 Million | $-17.56 Million | 0.562x | +187.00% |
| 2020-12-31 | $-14.05 Million | $9.07 Million | -0.646x | -119.14% |
| 2019-12-31 | $-5.60 Million | $-18.90 Million | 3.373x | +463.71% |
| 2018-12-31 | $18.20 Million | $-16.88 Million | -0.927x | -- |
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is … Read more